STREET - Somatostatin Treatment Experience Trial

#1708

Introduction: Somatostatin analogs (SSA) delay progress and decrease symptoms in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). It is not known whether patients’ experiences of injection treatment differ between different SSAs.

Aim(s): To investigate quality of life and treatment experience with SSA in patients with GEP-NETs.

Materials and methods: A cross-sectional study was performed in two Swedish NET centres. Patients with GEP-NET, older than 18 years, with SSA-treatment for less than 3 years and with Ki67<10% were eligible and identified from hospital databases. Patients were sent a questionnaire addressing practical aspects of, and patient anxiety during the most recent SSA injection.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Almquist M, Myrenfors P, Ström T, Kozlovacki G,

Keywords: somatostatin analogs, octreotide, lanreotide, quality of life, injection,